The Sudeep Pharma IPO is one of the most closely watched pharma IPO launches of the year, driven by the company’s strong position in mineral-based ingredients, speciality ingredients and its long-standing relationships across the pharmaceutical, food and nutrition industries. As a technology-led manufacturer with three manufacturing facilities, in-house technologies, and a global customer base across South America, Asia Pacific and international markets, the company is now preparing to list on the National Stock Exchange and BSE.
Sudeep Pharma IPO Timeline
(Sudeep Pharma IPO opens on November 21, 2025, and closes on November 25, 2025.)
| Event | Date |
|---|---|
| IPO Open Date | Fri, Nov 21, 2025 |
| IPO Close Date | Tue, Nov 25, 2025 |
| Basis of Allotment | Wed, Nov 26, 2025 |
| Initiation of Refunds | Thu, Nov 27, 2025 |
| Credit of Shares to Demat | Thu, Nov 27, 2025 |
| IPO Listing Date | Fri, Nov 28, 2025 |
| Cut-off for UPI Mandate | 5 PM on Nov 25, 2025 |
Sudeep Pharma IPO Details
| Detail | Information |
|---|---|
| IPO Date | Nov 21 to Nov 25, 2025 |
| Face Value | ₹1 per share |
| IPO Price Band | ₹563 to ₹593 per share |
| Lot Size | 25 Shares |
| Offer for Sale | 1,34,90,726 shares (₹800 Cr) |
| Fresh Issue | 16,02,024 shares (₹95 Cr) |
| Total Issue Size | 1,50,92,750 shares (₹895 Cr) |
| Issue Type | Book-building |
| Listing At | BSE, NSE |
| Pre-Issue Shares | 11,13,46,602 |
| Post-Issue Shares | 11,29,48,626 |
These ipo details are crucial for retail investors, non-institutional investors, and qualified institutional buyers assessing the opportunity.
Company Overview: Sudeep Pharma Ltd.
Sudeep Pharma Ltd. is one of India's leading producers of specialty and mineral-based ingredients used across pharmaceutical, food and nutrition industries. The company serves a diverse customer base including major names like Micro Labs, Intas Pharmaceuticals, Merck Group and many others across global markets.
Key highlights:
Strong footprint in international markets, including South America and the Asia-Pacific region.
A technology-driven manufacturer with in-house technologies, spray drying expertise, and capability to produce food-grade iron phosphate, liposomal preparations, and speciality nutrition ingredients.
The company operates in a high-barrier industry, supporting long-standing relationships and consistent demand.
Promoter group includes Sujit Bhayani, Shanil Sujit Bhayani, Avani Sujit Bhayani, and Sujeet Jaysukh Bhayani HUF, alongside shareholder Riva Resources Private Limited.
Manufacturing Facilities & Capabilities
Sudeep Pharma operates three manufacturing facilities located within the Nandesari facility (GIDC Estate). These include:
Nandesari Facility I
Additional units with production lines located strategically for efficient supply.
Technology-enabled units for spray drying, speciality ingredients, and nutrition-grade compounds.
The entire setup integrates in-house technologies allowing better quality control and lower dependence on external vendors.
The company’s position as a technology-led manufacturer gives it strong market leadership in speciality pharma and food & nutrition segments.
Industry Overview
The pharma is a technology-driven industry, and mineral-based ingredients form a critical input for formulations across:
Pharmaceutical APIs
Infant nutrition
Food & nutrition sectors
Specialty formulations
Liposomal preparations
With rising demand in domestic and international markets, and increasing reliance on high-purity speciality ingredients, Sudeep Pharma is competitively positioned to scale.
Capital Expenditure & Company Plans
A portion of the net proceeds from the fresh issue will be directed towards:
Capital expenditure for procurement of equipment
Strengthening its manufacturing facilities
Debottlenecking and capacity expansion
Funding working capital
General corporate purposes
This capex is expected to improve capacity utilisation and expand its diversified product portfolio.
Financial Performance
Below is the restated consolidated financial performance of Sudeep Pharma Ltd.
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 922.26 | 717.17 | 513.87 | 420.11 |
| Total Income | 130.08 | 511.33 | 465.38 | 438.26 |
| Profit After Tax | 31.27 | 138.69 | 133.15 | 62.32 |
| EBITDA | 48.57 | 199.28 | 187.76 | 98.64 |
| Net Worth | 688.32 | 497.53 | 359.07 | 226.29 |
| Reserves & Surplus | 668.52 | 481.11 | 354.59 | 221.88 |
| Total Borrowing | 135.97 | 135.25 | 75.03 | 82.26 |
These numbers show consistent growth in assets, strong profitability, and rising EBITDA supported by a global customer base.
IPO Allotment Details & Allotment Status
Retail investors can check the sudeep pharma ipo allotment and allotment status through the registrar MUFg Intime India Pvt once the basis of allotment is finalised.
Details will be available on:
MUFG Intime India website
BSE IPO allotment page
Updates via demat account and bank account SMS
IPO Listing & IPO Listing Date
The ipo listing date is Friday, November 28, 2025, on both NSE and BSE.
Given the company’s market leadership, diversified industries served, and presence in global markets, interest in the ipo listing is expected to be high. Grey market activity may provide early signals, though retail investors should rely on fundamentals.
Conclusion
The Sudeep Pharma IPO combines a robust business model, established relationships, three manufacturing facilities, and a diversified presence across pharmaceutical and nutrition industries. With a strong financial record and increasing demand for speciality and mineral-based ingredients, the company stands well-positioned for future expansion.
For investors seeking exposure to a steady, technology-driven ingredients manufacturer with global reach, this pharma IPO offers a compelling opportunity — provided they assess valuations, price band, business risks, and long-term prospects.
Disclaimer: The information provided in our blogs is for informational purposes only and should not be construed as financial, investment, or trading advice. Trading and investing in the securities market carries risk. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. Copyrighted and original content for your trading and investing needs.
© 2025 — Tradejini. All Rights Reserved.
